Literature DB >> 15665083

Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

Joel N H Stern1, Zsolt Illés, Jayagopala Reddy, Derin B Keskin, Masha Fridkis-Hareli, Vijay K Kuchroo, Jack L Strominger.   

Abstract

Myelin basic protein (MBP) is a major candidate autoantigen in multiple sclerosis (MS). Its immunodominant epitope, MBP 85-99, forms a complex with human leukocyte antigen (HLA)-DR2 with which multiple sclerosis is genetically associated. Copolymer 1 (Copaxone), a random amino acid copolymer [poly (Y,E,A,K)n] as well as two modified synthetic copolymers [poly (F,Y,A,K)n and poly (V,W,A,K)n] also form complexes with HLA-DR2 (DRA/DRB1*1501) and compete with MBP 85-99 for binding. Moreover, two high-affinity synthetic peptide 15-mers that could inhibit binding even more effectively were previously designed. Here, we show that further-modified peptide 15-mers inhibited even more strongly (in order J5 > J3 > J2) both the binding of MBP 85-99 to HLA-DR2 and IL-2 production by two MBP 85-99-specific HLA-DR2-restricted T cells. J5, J3, and J2 also suppressed both MBP 85-99-induced experimental autoimmune encephalomyelitis (EAE) in humanized mice and proteolipid protein 139-151-induced EAE in SJL/J mice. Moreover, none of these previously uncharacterized peptide inhibitors crossreacted with MBP 85-99- or proteolipid protein 139-151-specific T cells. In both cases, spleen and lymph node cultures stimulated with these peptides produced large amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of established T cell lines suppressed disease induction. These peptide 15-mers provide specific, nonrandom sequences that appear to be at least as effective as random copolymers in suppressing EAE in several models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665083      PMCID: PMC547868          DOI: 10.1073/pnas.0409022102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules.

Authors:  M Fridkis-Hareli; J L Strominger
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

2.  Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.

Authors:  N Kerlero de Rosbo; M Hoffman; I Mendel; I Yust; J Kaye; R Bakimer; S Flechter; O Abramsky; R Milo; A Karni; A Ben-Nun
Journal:  Eur J Immunol       Date:  1997-11       Impact factor: 5.532

3.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer; T Vollmer; L P Weiner; J S Wolinsky
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

4.  Regulation of experimental autoimmune encephalomyelitis by interleukin-12.

Authors:  J P Leonard; K E Waldburger; S J Goldman
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

5.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

6.  Identification of autoimmune T cells among in vivo expanded CD25+ T cells in multiple sclerosis.

Authors:  Z Illés; T Kondo; K Yokoyama; T Ohashi; T Tabira; T Yamamura
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

Review 7.  Role of Th1 and Th2 cells in autoimmune demyelinating disease.

Authors:  L Nagelkerken
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

8.  An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.

Authors:  L B Nicholson; J M Greer; R A Sobel; M B Lees; V K Kuchroo
Journal:  Immunity       Date:  1995-10       Impact factor: 31.745

9.  IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice.

Authors:  E Bettelli; M P Das; E D Howard; H L Weiner; R A Sobel; V K Kuchroo
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

10.  Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein.

Authors:  K J Smith; J Pyrdol; L Gauthier; D C Wiley; K W Wucherpfennig
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

View more
  13 in total

Review 1.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

2.  Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.

Authors:  Naoki Kobayashi; Paul Kiptoo; Hitomi Kobayashi; Rahmawati Ridwan; Stefan Brocke; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2008-08-03       Impact factor: 3.969

3.  Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice.

Authors:  Joel N H Stern; Derin B Keskin; Hong Zhang; Huijuan Lv; Zenichiro Kato; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

4.  Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.

Authors:  Joshua O Sestak; Amir Fakhari; Ahmed H Badawi; Teruna J Siahaan; Cory Berkland
Journal:  AAPS J       Date:  2014-09-06       Impact factor: 4.009

5.  Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

Authors:  Cassandra E Smith; Todd N Eagar; Jack L Strominger; Stephen D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

6.  T cell receptors in an IL-10-secreting amino acid copolymer-specific regulatory T cell line that mediates bystander immunosuppression.

Authors:  Hong Zhang; Joel N H Stern; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-09       Impact factor: 11.205

7.  Genetically modified hematopoietic stem/progenitor cells that produce IL-10-secreting regulatory T cells.

Authors:  Sze-Ling Ng; Ester Leno-Duran; Dibyendu Samanta; Steven C Almo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-25       Impact factor: 11.205

8.  A Modified Peptide Derived from Goodpasture Autoantigen Arrested and Attenuated Kidney Injuries in a Rat Model of Anti-GBM Glomerulonephritis.

Authors:  Yue Shi; Xiao-Yu Jia; Qiu-Hua Gu; Miao Wang; Zhao Cui; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2019-10-30       Impact factor: 10.121

9.  Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein.

Authors:  Zhitao Ru; Wenjun Xiao; Anthony Pajot; Zhihua Kou; Shihui Sun; Bernard Maillere; Guangyu Zhao; David M Ojcius; Yu-Chun Lone; Yusen Zhou
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

10.  Regulation of EAE by spontaneously generated IL-10-secreting regulatory T cells in HLA-DR15/TCR.Ob1A12 double transgenic mice.

Authors:  Ester Leno-Durán; Sze-Ling Ng; Jack L Strominger
Journal:  Immunology       Date:  2021-03-22       Impact factor: 7.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.